Wegovy Weight Loss Pen 0.5mg is approved by the FDA for managing excess weight and helping to prevent cardiovascular complications in individuals with obesity or overweight. The medication is administered subcutaneously once a week.
Wegovy injections contain the active ingredient semaglutide, which activates GLP-1 receptors in the brain. This helps reduce appetite and slows gastric emptying, leading to prolonged satiety, reduced food intake, and subsequent weight loss.
Wegovy is FDA-approved for weight loss and long-term weight management in:
The FDA has also approved Wegovy for reducing the risk of cardiovascular complications such as heart attack or stroke in adults with cardiovascular disease and either obesity or overweight.
Wegovy is used in combination with a reduced-calorie diet and increased physical activity.
|
Dose |
Weeks |
Month |
|
0.25 mg |
1 - 4 |
first |
|
0.5 mg |
5 - 8 |
second |
|
1 mg |
9 - 12 |
third |
|
1.7 mg |
13 - 16 |
fourth |
|
1.7 or 2.4 mg |
Week 17 and beyond |
fifth and onward |
Wegovy injections may cause the following side effects:
Wegovy injections should not be used in cases of:
Consult a doctor before using Wegovy, especially in cases of:
It may take some time to see results from Wegovy injections, but after one year of use, an average weight loss of approximately 15% is expected.